Table 2 The outcomes gathered from experiences with ECMO in COVID-19
From: COVID-19 and ECMO: the interplay between coagulation and inflammation—a narrative review
Study | Type | Location | N | ICU admission | ARDS | ECMO | Overall mortality | ECMO mortality |
|---|---|---|---|---|---|---|---|---|
Chen et al. [65] | Retrospective observational | Wuhan Jinyintan Hospital | 99 | 23 (23.2%) | 17 (17.2%) | 3 (3.0%) | 11 (11.1%) | NA |
Guan et al. [3] | Cross-sectional | 552 hospitals in 30 provinces, autonomous regions, and municipalities in mainland China | 1099 | 55 (5.0%) | 37 (3.4%) | 5 (0.5%) | 15 (1.4%) | NA |
Huang et al. [39] | Cross-sectional | Jin Yin-tan Hospital, Wuhan, China | 41 | 13 (31.7%) | 12 (29.3%) | 2 (4.9%) | 6 (14.6%) | NA |
Liu et al. [66] | Retrospective observational | Nine tertiary hospitals in Hubei | 137 | NA | 34 (24.8%)* | 0 (0.0%) | 16 (11.7%) | NA |
Ruan et al. [31] | Retrospective multicenter study | Jin Yin-tan Hospital and Tongji Hospital | 150 | 41 (27.3%) | 62 (41.3%) | 7 (4.7%) | 68 (45.3%) | 7 (100%) |
Shen et al. [67] | Case series | Shenzhen Third People’s Hospital in Shenzhen, China | 5 | 5 (100%) | 5 (100%) | 1 (20.0%) | 0 (0.0%) | 0 (0.0%) |
Tang et al. [17] | Retrospective case-control study | Wuhan Pulmonary Hospital | 73 | 73 (100%) | 73 (100%) | 10 (13.7%) | 21 (28.3%) | NA |
Wang et al. [16] | Case series | Zhongnan Hospital of Wuhan University in Wuhan, China | 138 | 36 (26.1%) | 22 (15.9%) | 4 (2.9%) | 6 (4.3%) | NA |
Wu et al. [58] | Retrospective cohort study | Wuhan Jinyintan Hospital | 201 | 53 (26.4%) | 84 (41.8%) | 1 (0.5%) | 44 (21.9%) | NA |
Yang et al. [68] | Retrospective observational | Wuhan Jin Yin-tan hospital (Wuhan, China) | 710 | 52 (7.3%) | 35 (4.9%) | 6 (0.8%) | 32 (4.5%) | 5 (83.3%) |
Zhou et al. [32] | Retrospective cohort study | Jinyintan Hospital and Wuhan Pulmonary Hospital | 191 | 50 (26.2%) | 59 (30.9%) | 3 (1.6%) | 54 (28.3%) | 3 (100.0%) |